Earlier CMS Review Could Improve Drug Labels, Ex-FDA Official Says

 
• By Sarah Karlin-Smith
picture of a generic drug label, zoomed in over the side effects section
More eyes and perspectives on Rx labels premarket might help avoid post-market payer complications. • Source: Shutterstock

More from US FDA

More from Agency Leadership